Clinical Trials Logo

Filter by:
NCT ID: NCT03490851 Completed - Satiety Clinical Trials

The Effect of a Breakfast Meal Containing Oat β-glucan on Food Intake at a Subsequent Meal in Normal-weight and Overweight Subjects

Start date: May 7, 2017
Phase: N/A
Study type: Interventional

The objectives of this study are to determine, in normal-weight and overweight subjects the effect of: Primary: oatmeal containing 4 g oat β-glucan on food intake at a subsequent meal compared to Cream of Rice cereal. Secondary: (i) oatmeal containing 2 g oat β-glucan on food intake at a subsequent meal compared to Cream of Rice cereal; and (ii) oatmeal containing 2g, 4g and 4g low MW oat beta-glucan on subjective appetite ratings, gastric emptying, postprandial responses of glucose, insulin, ghrelin and PYY levels compared to those elicited by Cream of Rice cereal. In addition, the relationship between amount, MW and viscosity of OBG and the primary and secondary objectives will be determined.

NCT ID: NCT03490721 Completed - Clinical trials for Premature Baby 26 to 32 Weeks

Effects of Clustering Care on the Physiological Stability of Preterm Infants.

Start date: September 12, 2018
Phase: N/A
Study type: Interventional

This crossover design experimental study aims to compare the physiological stability of premature newborns during and after a cluster of care compared to a period when they receive standard non clustered care at the neonatal unit.

NCT ID: NCT03490669 Completed - Ovarian Cancer Clinical Trials

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

Start date: May 21, 2018
Phase: Phase 1
Study type: Interventional

This is a 2-part study to evaluate the safety and antitumor activity of MSC-1. MSC-1 is a first-in-class, humanized monoclonal antibody (IgG1) which binds to the immunosuppressive human cytokine Leukemia Inhibitory Factor (LIF), and is intended to treat adult patients with Advanced Solid Tumors. In part 1, multiple dose levels of MSC-1 in patients with advanced solid tumors will be studied to determine the recommended dose for further evaluation of safety and efficacy in Part 2.

NCT ID: NCT03490539 Completed - Autoimmune Diseases Clinical Trials

Disease-Modifying Treatments for Myasthenia Gravis

PROMISE-MG
Start date: May 7, 2018
Phase:
Study type: Observational [Patient Registry]

This study is designed to address the evidence gaps in a real-world setting and help patients with MG choose treatments that are best suited to them. It is a prospective, multicenter observational cohort study of comparative effectiveness of MG treatments, with a patient-centered primary outcome measure, to guide clinicians, patients and payers regarding the choice of treatment options for this chronic and serious disease. Primary: To compare the effectiveness of azathioprine (AZT) and mycophenolate mofetil (MMF). Secondary: To compare the outcomes in patients receiving an adequate dose and duration of AZT or MMF over the 2-3 year study period, vs. patients not receiving adequate doses and duration of these agents

NCT ID: NCT03489967 Completed - Type 1 Diabetes Clinical Trials

Treatment of Hypoglycemia in Type 1 Diabetes

Start date: April 18, 2018
Phase: N/A
Study type: Interventional

According to guidelines, when a mild-to-moderate hypoglycemia occurs (capillary blood glucose < 4.0 mmol/L), 15-20g of rapidly absorbed carbohydrates should be ingested. Patients should re-test and re-ingest 15-20g carbohydrates every 15 minutes until they recover from hypoglycemia. These recommendations were principally based on two studies conducted in the 80s before the introduction of intensive insulin therapy secondary to the DCCT trial and with insulin formulations with largely different pharmacokinetic profiles from current insulin analogs. Recent studies suggest that with current insulin analogs and intensive therapeutic approach, 15g of carbohydrates may be insufficient to rapidly correct an important proportion of hypoglycemic episodes. It is thus important to determine if the recommended hypoglycemia treatment remains the recommendation.

NCT ID: NCT03489694 Completed - Allergic Reaction Clinical Trials

Repeatability and Reproducibility of Skin Test Endpoint Titration

Start date: May 4, 2018
Phase:
Study type: Observational

This study will examine the within-tester repeatability and between-tester reproducibility of skin test endpoint titrations performed in those with allergic sensitivities.

NCT ID: NCT03489369 Completed - Lymphoma Clinical Trials

Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Start date: May 8, 2018
Phase: Phase 1
Study type: Interventional

This is the first study to test Sym022 in humans. The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.

NCT ID: NCT03489343 Completed - Lymphoma Clinical Trials

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Start date: May 24, 2018
Phase: Phase 1
Study type: Interventional

This was the first study to test Sym023 in humans. The primary purpose of this study was to see if Sym023 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.

NCT ID: NCT03488992 Completed - Metabolic Syndrome Clinical Trials

Effect of a MVM Dietary Supplement on Indices of Human Health

Start date: January 10, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the health benefits of a recently developed multimineral/multivitamin/phytochemical (MVM/phytochemical) nutritional supplement. This newly developed supplement - an advancement of a previous formula designed to enhance human health by providing RDA-levels of essential vitamins and minerals - contains eight phytochemicals selected to address fruit and vegetable undernutrition, and chosen on the basis that: 1) published research from cell culture, animal model and, when available, human clinical work, suggests that it may benefit human health, and 2) it is considered safe for human ingestion at proposed levels of consumption.

NCT ID: NCT03488355 Completed - Clinical trials for Urinary Tract Infections

Modified Reporting From Indwelling Catheters

Start date: November 5, 2018
Phase: N/A
Study type: Interventional

Positive urine cultures collected from indwelling catheters from inpatients will be randomized to standard reporting or modified reporting. Physician antibiotic treatment decisions will be prospectively observed and determined to be appropriate or inappropriate. The hypothesis is that modified reporting will lead to an increase in the percentage of appropriate therapy without an increase in pyelonephritis or sepsis.